Importantly, inhibition of Syk blocks CLL cell migration and adhesion [160, 166], and this may explain why reduction in lymphadenopathy is observed when this agent has been used in clinical trials. This evidence concerns the gene SYK and B-cell chronic lymphocytic leukemia.